Jianxiang Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jianxiang Chen has a total of 162 co-authors. Here are the top co-authors by number of shared publications:
Menglan Wang
Zhejiang Provincial Key Laboratory of Anti‐Cancer Chinese Medicines and Natural Medicines School of Pharmacy Hangzhou Normal University Department of Hepatology the Affiliated Hospital of Hangzhou Normal University Hangzhou 311121 China
13 shared publicationsMengqing Sun
Zhejiang Provincial Key Laboratory of Anti‐Cancer Chinese Medicines and Natural Medicines School of Pharmacy Hangzhou Normal University Department of Hepatology the Affiliated Hospital of Hangzhou Normal University Hangzhou 311121 China
12 shared publicationsHeng Dong
Zhejiang Provincial Key Laboratory of Anti‐Cancer Chinese Medicines and Natural Medicines School of Pharmacy Hangzhou Normal University Department of Hepatology the Affiliated Hospital of Hangzhou Normal University Hangzhou 311121 China
11 shared publications- Yiting Qiao
Division of Hepatobiliary and Pancreatic Surgery Department of Surgery The First Affiliated Hospital Zhejiang University School of Medicine Hangzhou China
10 shared publications Cunjie Chang
School of Pharmacy and Department of Hepatology, the Affiliated Hospital of Hangzhou Normal University Hangzhou Normal University Hangzhou P. R. China
7 shared publicationsFangtian Bu
Zhejiang Provincial Key Laboratory of Anti‐Cancer Chinese Medicines and Natural Medicines School of Pharmacy Hangzhou Normal University Department of Hepatology the Affiliated Hospital of Hangzhou Normal University Hangzhou 311121 China
7 shared publications
Latest Publications
- Open Access
- 22 May 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
RNA splicing in cancer cell death regulation: shedding light on the molecular mechanisms and potential clinical applications
Alternative splicing (AS) is a ubiquitous posttranscriptional regulatory mechanism in eukaryotes through which proteins with various structures and functions are produced from a single pre-mRNA. It is performed by the spliceosome and regulated by both cis-acting elements and trans-acting splicing factors. The common modes of regulatory cell death (RCD) include apoptosis, necroptosis, autophagy, pyroptosis and ferroptosis, and dysregulation of these cell death modes can lead to tumorigenesis. The abnormal expression of spliceosome components and splicing factors, or aberrant splicing events, modulates RCD and contributes to the occurrence and progression of cancer. This review focuses on the roles of AS in tumour RCD and the underlying mechanism through which AS modulates different modes of RCD. Moreover, we summarise some potential clinical applications of targeting AS–RCD axes. This review offers systematic and mechanistic insights into tumorigenesis from the perspectives of AS and RCD, and the ultimate objective is to translate these findings into targeted therapies for cancer treatment.
- 22 May 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Open AccessRNA splicing in cancer cell death regulation: shedding light on the molecular mechanisms and potential clinical applications
Alternative splicing (AS) is a ubiquitous posttranscriptional regulatory mechanism in eukaryotes through which proteins with various structures and functions are produced from a single pre-mRNA. It is performed by the spliceosome and regulated by both cis-acting elements and trans-acting splicing factors. The common modes of regulatory cell death (RCD) include apoptosis, necroptosis, autophagy, pyroptosis and ferroptosis, and dysregulation of these cell death modes can lead to tumorigenesis. The abnormal expression of spliceosome components and splicing factors, or aberrant splicing events, modulates RCD and contributes to the occurrence and progression of cancer. This review focuses on the roles of AS in tumour RCD and the underlying mechanism through which AS modulates different modes of RCD. Moreover, we summarise some potential clinical applications of targeting AS–RCD axes. This review offers systematic and mechanistic insights into tumorigenesis from the perspectives of AS and RCD, and the ultimate objective is to translate these findings into targeted therapies for cancer treatment.
- Open Access
- 12 January 2026
- Published by Wiley in Advanced Science
- Vol. 13 (11) , e11887
Elemene Augments the Effects of Anti‐PD‐1 Immunotherapy on Hepatocellular Carcinoma by Regulating the miR‐130a‐5p/SPP/MHC‐I Axis
Immune checkpoint inhibitors, particularly PD‐1 inhibitors, constitute the cornerstone of first‐line treatment for hepatocellular carcinoma (HCC). However, suboptimal overall response rates persist alongside dual challenges: immune‐related toxicities and immunosuppressive tumor microenvironment. Combination therapies represent a pivotal strategy to overcome these limitations. In recent years, traditional Chinese medicine has gained significant attention. Elemene, a small‐molecule compound derived from Curcuma wenyujin , has garnered attention for its immunomodulatory potential and demonstrates clinical efficacy in combination therapies. Nevertheless, its synergistic mechanisms with immunotherapy remain incompletely characterized. This study demonstrates for the first time that elemene modulates the miR‐130a‐5p/SPP/MHC‐I axis, resulting in an enhanced diversity and abundance of antigen/MHC‐I complexes on the surface of HCC cells. This mechanism promotes the recognition and elimination of HCC cells by cytotoxic T lymphocytes, thereby augmenting the antitumor immune efficacy of PD‐1. Moreover, the functional significance of the miR‐130a‐5p/SPP/MHC‐I axis in modulating the tumor immune microenvironment is systematically validated through in vitro and in vivo HCC models, as well as in clinical patient specimens. These findings underscore the potential of combining elemene with anti‐PD‐1 therapy as a safe and effective treatment strategy for HCC, offering significant translational promise for improving patient outcomes.
- 12 January 2026
- Published by Wiley in Advanced Science
- Vol. 13 (11) , e11887
Open AccessElemene Augments the Effects of Anti‐PD‐1 Immunotherapy on Hepatocellular Carcinoma by Regulating the miR‐130a‐5p/SPP/MHC‐I Axis
Immune checkpoint inhibitors, particularly PD‐1 inhibitors, constitute the cornerstone of first‐line treatment for hepatocellular carcinoma (HCC). However, suboptimal overall response rates persist alongside dual challenges: immune‐related toxicities and immunosuppressive tumor microenvironment. Combination therapies represent a pivotal strategy to overcome these limitations. In recent years, traditional Chinese medicine has gained significant attention. Elemene, a small‐molecule compound derived from Curcuma wenyujin , has garnered attention for its immunomodulatory potential and demonstrates clinical efficacy in combination therapies. Nevertheless, its synergistic mechanisms with immunotherapy remain incompletely characterized. This study demonstrates for the first time that elemene modulates the miR‐130a‐5p/SPP/MHC‐I axis, resulting in an enhanced diversity and abundance of antigen/MHC‐I complexes on the surface of HCC cells. This mechanism promotes the recognition and elimination of HCC cells by cytotoxic T lymphocytes, thereby augmenting the antitumor immune efficacy of PD‐1. Moreover, the functional significance of the miR‐130a‐5p/SPP/MHC‐I axis in modulating the tumor immune microenvironment is systematically validated through in vitro and in vivo HCC models, as well as in clinical patient specimens. These findings underscore the potential of combining elemene with anti‐PD‐1 therapy as a safe and effective treatment strategy for HCC, offering significant translational promise for improving patient outcomes.
- Top Cited PapersOpen Access
- 24 November 2025
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 23 (1) , 733
Collagenase-mediated extracellular matrix targeting for enhanced drug penetration and therapeutic efficacy in nanoscale delivery systems for cancer therapy
The highly fibrotic extracellular matrix (ECM) constitutes a major barrier that restricts the penetration and delivery efficiency of anticancer drugs, part
- 24 November 2025
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 23 (1) , 733
Top Cited PapersOpen AccessCollagenase-mediated extracellular matrix targeting for enhanced drug penetration and therapeutic efficacy in nanoscale delivery systems for cancer therapy
The highly fibrotic extracellular matrix (ECM) constitutes a major barrier that restricts the penetration and delivery efficiency of anticancer drugs, part
- Open Access
- 24 September 2025
- Published by Wiley in Cancer Science
- Vol. 116 (12) , 3326-3336
N6 ‐Methyladenosine‐Modified circNEK11 Promotes Hepatocellular Carcinoma Progression via the miR ‐1236‐3p/ GPX2 Axis
CircRNAs are endogenous covalently closed circular RNAs, and previous studies have validated their key regulatory roles in malignant tumors; however, the specific role and regulatory mechanism of circNEK11 in hepatocellular carcinoma (HCC) remain unclear. Here, we discovered that circNEK11 back‐spliced from exons 12, 13, 14, and 15 of the NEK11 gene is significantly upregulated in HCC tissues, especially recurrent HCC tissues. YTHDC1 functions as a reader of m6A‐modified circNEK11 and facilitates its cytoplasmic export. circNEK11 promotes HCC cell oncogenic functions in vitro and HCC growth in vivo. Mechanistically, circNEK11 directly binds to miR‐1236‐3p to regulate GPX2 expression, thus promoting HCC progression and recurrence. Collectively, our findings suggest that circNEK11 is a potential biomarker and target for HCC diagnosis and treatment.
- 24 September 2025
- Published by Wiley in Cancer Science
- Vol. 116 (12) , 3326-3336
Open AccessN6 ‐Methyladenosine‐Modified circNEK11 Promotes Hepatocellular Carcinoma Progression via the miR ‐1236‐3p/ GPX2 Axis
CircRNAs are endogenous covalently closed circular RNAs, and previous studies have validated their key regulatory roles in malignant tumors; however, the specific role and regulatory mechanism of circNEK11 in hepatocellular carcinoma (HCC) remain unclear. Here, we discovered that circNEK11 back‐spliced from exons 12, 13, 14, and 15 of the NEK11 gene is significantly upregulated in HCC tissues, especially recurrent HCC tissues. YTHDC1 functions as a reader of m6A‐modified circNEK11 and facilitates its cytoplasmic export. circNEK11 promotes HCC cell oncogenic functions in vitro and HCC growth in vivo. Mechanistically, circNEK11 directly binds to miR‐1236‐3p to regulate GPX2 expression, thus promoting HCC progression and recurrence. Collectively, our findings suggest that circNEK11 is a potential biomarker and target for HCC diagnosis and treatment.
- 13 September 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 328 (Pt 2) , 147657
The interplay between post-transcriptional RNA regulation and Wnt/β-Catenin signaling in cancer: A Review
- 13 September 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 328 (Pt 2) , 147657
The interplay between post-transcriptional RNA regulation and Wnt/β-Catenin signaling in cancer: A Review
- Open Access
- 3 July 2025
- Published by Elsevier in Journal of Advanced Research
- Vol. 82, 803-819
Redistribution of super-enhancers promotes malignancy in human hepatocellular carcinoma
- 3 July 2025
- Published by Elsevier in Journal of Advanced Research
- Vol. 82, 803-819
Open AccessRedistribution of super-enhancers promotes malignancy in human hepatocellular carcinoma
- Open Access
- 24 June 2025
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 16, 1598525
Key genes of vitamin D metabolism and their roles in the risk and prognosis of cancer
Vitamin D is an essential vitamin for normal human metabolism and plays pivotal roles in various biological processes, such as maintaining calcium and phosphorus balance, regulating immune responses, and promoting cell differentiation while inhibiting proliferation. Vitamin D is obtained through sunlight exposure and diet, and is metabolized into its active form via hydroxylation in liver and kidney. Vitamin D deficiency is linked to various diseases, including skeletal disorders, diabetes, and cardiovascular diseases. Recent epidemiology and oncology research have demonstrated that serum vitamin D level, as well as genetic polymorphisms and expression dysregulation of genes related with vitamin D metabolism, have significantly influences on the incidence and prognosis of various types of cancer, including breast cancer, prostate cancer, liver cancer, gastrointestinal malignancy, and hematologic malignancies. The mechanisms linking vitamin D metabolism dysregulation to malignancy are multifactorial, such as the alteration in cell metabolism, proliferation, differentiation, and tumor microenvironment. These findings suggest potential therapeutic benefits of targeting the vitamin D signaling pathway for the diagnosis and treatment of cancer. However, there is still a lack of clinical applications regarding the knowledge of vitamin D metabolic pathway, and future research is urgently needed to illustrate the underlying mechanisms for the rationale design of clinical trials. Therefore, this review summarizes the metabolic pathways of vitamin D and its association with cancer, highlighting the importance of genetic polymorphisms and expression dysregulation of genes involved in vitamin D metabolism in cancer susceptibility and prognosis.
- 24 June 2025
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 16, 1598525
Open AccessKey genes of vitamin D metabolism and their roles in the risk and prognosis of cancer
Vitamin D is an essential vitamin for normal human metabolism and plays pivotal roles in various biological processes, such as maintaining calcium and phosphorus balance, regulating immune responses, and promoting cell differentiation while inhibiting proliferation. Vitamin D is obtained through sunlight exposure and diet, and is metabolized into its active form via hydroxylation in liver and kidney. Vitamin D deficiency is linked to various diseases, including skeletal disorders, diabetes, and cardiovascular diseases. Recent epidemiology and oncology research have demonstrated that serum vitamin D level, as well as genetic polymorphisms and expression dysregulation of genes related with vitamin D metabolism, have significantly influences on the incidence and prognosis of various types of cancer, including breast cancer, prostate cancer, liver cancer, gastrointestinal malignancy, and hematologic malignancies. The mechanisms linking vitamin D metabolism dysregulation to malignancy are multifactorial, such as the alteration in cell metabolism, proliferation, differentiation, and tumor microenvironment. These findings suggest potential therapeutic benefits of targeting the vitamin D signaling pathway for the diagnosis and treatment of cancer. However, there is still a lack of clinical applications regarding the knowledge of vitamin D metabolic pathway, and future research is urgently needed to illustrate the underlying mechanisms for the rationale design of clinical trials. Therefore, this review summarizes the metabolic pathways of vitamin D and its association with cancer, highlighting the importance of genetic polymorphisms and expression dysregulation of genes involved in vitamin D metabolism in cancer susceptibility and prognosis.
- Open Access
- 28 April 2025
- Published by Elsevier in Phytomedicine
- Vol. 143, 156808
The anti-metastatic effect of elemene in human hepatocellular carcinoma is potentially mediated by inhibiting a novel driver-circBPTF
- 28 April 2025
- Published by Elsevier in Phytomedicine
- Vol. 143, 156808
Open AccessThe anti-metastatic effect of elemene in human hepatocellular carcinoma is potentially mediated by inhibiting a novel driver-circBPTF
- Open Access
- 1 November 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1491802
Targeting programmed cell death via active ingredients from natural plants: a promising approach to cancer therapy
Cancer is a serious public health problem in humans, and prevention and control strategies are still necessary. Therefore, the development of new therapeutic drugs is urgently needed. Targeting programmed cell death, particularly via the induction of cancer cell apoptosis, is one of the cancer treatment approaches employed. Recently, an increasing number of studies have shown that compounds from natural plants can target programmed cell death and kill cancer cells, laying the groundwork for use in future anticancer treatments. In this review, we focus on the latest research progress on the role and mechanism of natural plant active ingredients in different forms of programmed cell death, such as apoptosis, autophagy, necroptosis, ferroptosis, and pyroptosis, to provide a strong theoretical basis for the clinical development of antitumor drugs.
- 1 November 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1491802
Open AccessTargeting programmed cell death via active ingredients from natural plants: a promising approach to cancer therapy
Cancer is a serious public health problem in humans, and prevention and control strategies are still necessary. Therefore, the development of new therapeutic drugs is urgently needed. Targeting programmed cell death, particularly via the induction of cancer cell apoptosis, is one of the cancer treatment approaches employed. Recently, an increasing number of studies have shown that compounds from natural plants can target programmed cell death and kill cancer cells, laying the groundwork for use in future anticancer treatments. In this review, we focus on the latest research progress on the role and mechanism of natural plant active ingredients in different forms of programmed cell death, such as apoptosis, autophagy, necroptosis, ferroptosis, and pyroptosis, to provide a strong theoretical basis for the clinical development of antitumor drugs.